Does discovery of clonal hematopoiesis on liquid biopsy for solid tumors change your treatment approach in terms of which chemotherapy to offer for the solid tumor?

Topics: Hematologic Malignancies • Medical Oncology • Hematology • Solid organ malignancy • Malignancy

Answer from: Medical Oncologist at Academic Institution

CHIP findings are relatively common. A small percentage of patients with CHIP abnormalities will evolve into a Hematological malignancy depending on the mutation in the 1-2% range. I am unaware of any data that indicates that this percentage increases due to treatment for solid tumors. Therefore, I ...

Comments

at Northwestern University
I am in agreement, though I will submit that this ...

Related Questions